BenchSci
AI-powered platform for understanding disease biology and accelerating drug discovery.
About
Technology stack
detected 2026-06-17No comments yet. Be the first to share your take.
What does BenchSci do?
BenchSci is building the world's first neuro-symbolic AI platform, ASCEND, to help scientists understand disease biology and accelerate drug discovery. ASCEND leverages a Biological Evidence Knowledge Graph (BEKG) and advanced AI to provide insights from diverse scientific data, including publications, multi-omics, and clinical trials. This platform aims to transform the drug discovery process by enabling R&D teams to go from hypothesis to successful experiment faster.
How much funding has BenchSci raised?
BenchSci has raised a total of $257M in funding. The most recent round on record is Series D.
Where is BenchSci headquartered?
BenchSci is headquartered in Toronto, Canada.
When was BenchSci founded?
BenchSci was founded in 2015.
What industry does BenchSci operate in?
BenchSci operates in Biotech, Drug Discovery, AI-Driven Drug Discovery, Neuro-Symbolic AI, Biological Evidence Knowledge Graph, Life Sciences.
How many employees does BenchSci have?
BenchSci has approximately 274 people on record.